Drugs / QLC5513
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07272590 | Dec 2025 → Jun 2027 expected | metastatic neoplasm | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07509515 | Apr 2026 → Sep 2027 expected | triple-negative breast carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLC5513 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07272590 ↗ |
| Route | Intravenous | “QLC5513 16 mg/kg intravenously” NCT07509515 ↗ |